Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Aptose Biosciences Inc. (T:APS)

Business Focus: Biotechnology & Medical Research (NEC)

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for APS within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jan 30, 2023 07:00 ET
Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia
Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today announced the 120 mg monotherapy dosing of patients in the APTIVATE Phase 1/2 clinical trial of tuspetinib (formerly HM43239), an oral, mutation agnostic tyrosine kinase inhibitor...
Read full article
Dec 28, 2022 07:30 ET
Aptose Biosciences to Present at Biotech Showcase™ 2023 Conference
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman,...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
1.68
--
--
Price to Sales - TTM
--
6.73
4.98
Price to Book - most recent quarter
1.50
2.21
1.78
Price to Cash Flow per share - TTM
--
13.43
9.83
Price to Free Cash Flow per share - TTM
--
33.71
13.14
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jan 15, 2023184,746-25,565
Dec 31, 2022210,31111,315
Dec 15, 2022198,9964,379
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Aptose Biosciences Inc. is a Canada-based clinical stage precision oncology biotechnology company. It is engaged in advancing kinase inhibitors to treat unmet medical needs in life-threatening cancers, such as acute myeloid leukemia (AML), certain B-cell malignancies, high-risk myelodysplastic syndrome (MDS) and other hematologic malignancies. Its HM43239 is being evaluated in an international Phase I/II study in patients with relapsed or refractory AML. Its Luxeptinib is being evaluated in a Phase I a/b trial in patients with relapsed or refractory B cell malignancies, and in a separate Phase I a/b trial in patients with relapsed or refractory AML or high-risk MDS. Its APTO-253 is a small molecule MYC oncogene inhibitor at the Phase Ia/b clinical trial stage of development for the treatment of patients with relapsed or refractory (R/R) blood cancers, including AML and high-risk MDS. Its APL-581 is a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program.

See business summary

 

Twitter

Search (past week) for $APS.CA

  • No tweets found